A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

Clinical trial NCT05450692 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05450692
Sponsor: AstraZeneca
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Advanced or Metastatic Non-Small Cell Lung Cancer

Start date: 2022-09-15
Primary completion: 2025-10-06
Enrollment: 594

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.